The N9831 GWAS study identified genetic associations of the maximum decline in LVEF at six novel loci (LDB2, BRINP1, chr6 intergenic, RAB22A, TRPC6, and LINC01060) in the subset of patients who were treated with chemotherapy plus trastuzumab (p < 1 × 10−5) and in the same patient group, with the CBR3 V244M variant (p < 0.05), which has previously been associated with anthracycline-induced cardiomyopathy and heart failure, summarized in (8). Here, CBR3 is linked to heart failure.